明德生物
(002932)
| 流通市值：26.78亿 | | | 总市值：39.90亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 225,617,843.38 | 154,270,388.52 | 60,963,422.3 | 749,536,774.56 |
| 营业收入 | 225,617,843.38 | 154,270,388.52 | 60,963,422.3 | 749,536,774.56 |
| 二、营业总成本 | 319,893,245.81 | 212,168,994.95 | 104,189,807.01 | 720,146,379.19 |
| 营业成本 | 108,759,792.33 | 68,776,065.62 | 36,409,334.65 | 342,703,065.78 |
| 税金及附加 | 992,146.35 | 703,190.21 | 305,598.68 | 2,250,211.6 |
| 销售费用 | 78,658,773.4 | 54,932,921.56 | 24,076,564 | 115,945,141.24 |
| 管理费用 | 51,979,156.29 | 37,486,649.12 | 18,843,544.05 | 112,638,453.08 |
| 研发费用 | 86,244,236.06 | 55,224,582.79 | 27,181,929.06 | 141,415,136.54 |
| 财务费用 | -6,740,858.62 | -4,954,414.35 | -2,627,163.43 | 5,194,370.95 |
| 其中:利息费用 | 470,919.47 | - | - | 10,498,964.25 |
| 其中:利息收入 | 8,205,047.52 | 5,175,296.41 | - | 4,385,909.12 |
| 加:公允价值变动收益 | 637,059.61 | 637,059.61 | - | 4,589,114.71 |
| 加:投资收益 | 78,456,046.18 | 54,864,143.65 | 26,856,887.97 | 120,550,338.17 |
| 资产处置收益 | 82,278.11 | 310,788.39 | -36,007.72 | 307,817.69 |
| 资产减值损失(新) | 0 | 0 | - | 4,753,258.38 |
| 信用减值损失(新) | 26,852,344.74 | 1,899,068.8 | -6,881,817.36 | -79,952,184.94 |
| 其他收益 | 70,528,745.56 | 70,295,279.6 | 57,659,937 | 65,555,715.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 82,281,071.77 | 70,107,733.62 | 34,372,615.18 | 145,194,454.94 |
| 加:营业外收入 | 338,528.65 | 177,073.45 | 125,224.27 | 877,517.01 |
| 减:营业外支出 | 4,544,957.62 | 2,569,522.51 | 375,620.14 | 6,182,489.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 78,074,642.8 | 67,715,284.56 | 34,122,219.31 | 139,889,482.45 |
| 减:所得税费用 | 15,710,870.64 | 12,943,750.62 | 6,014,057.11 | 70,673,084.48 |
| 六、净利润 | 62,363,772.16 | 54,771,533.94 | 28,108,162.2 | 69,216,397.97 |
| 持续经营净利润 | 62,363,772.16 | 54,771,533.94 | 28,108,162.2 | 69,216,397.97 |
| 归属于母公司股东的净利润 | 80,938,367.97 | 65,162,572.86 | 32,052,081.48 | 74,925,916.55 |
| 少数股东损益 | -18,574,595.81 | -10,391,038.92 | -3,943,919.28 | -5,709,518.58 |
| (一)基本每股收益 | 0.35 | 0.28 | 0.14 | 0.33 |
| (二)稀释每股收益 | 0.35 | 0.28 | 0.14 | 0.33 |
| 九、综合收益总额 | 62,363,772.16 | 54,771,533.94 | 28,108,162.2 | 69,216,397.97 |
| 归属于母公司股东的综合收益总额 | 80,938,367.97 | 65,162,572.86 | 32,052,081.48 | 74,925,916.55 |
| 归属于少数股东的综合收益总额 | -18,574,595.81 | -10,391,038.92 | -3,943,919.28 | -5,709,518.58 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-30 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |